I'm more positive with WDDD because WDDD isn't fighting Google. ACTI is not google and doesn't have google's influence and money.
agree and with WDDD there's not much to lose. At 12 cents there's not much to lose like there was with Vringo at 3
worst example of a launch ever. Sanofi is showing they want to focus on Toujeo and don'r really care about Afrezza.
i'm sure activation wants this in court and activation knows that vringo just lost on appeal
With the terrible marketing job Sanofi has done its evident that MNKD could have done a the same or better job without Sanofi
Afrezza is even underperforming Exubera, the first inhaled insulin drug, launched by Pfizer in 2006. Exubera was a commercial failure, forcing Pfizer (PFE) to abandon the product after one year. With the terrible marketing job Sanofi has done its evident that MNKD could have done a the same or better job without Sanofi
and the idiot pumpers are still running their mouths here. You were done in and it wasn't the shorts who killed you. It was the board of directors who sold at every chance they could that drove the stock down.